IDC:第三季中國5G手機出貨量達48.5萬台
調查機構IDC發表的報告指出,隨著5G商用推出,今年第三季中國5G手機出貨量達48.5萬台,大部分均為700美元(下同)以上的旗艦機,但亦有一些是來自低價品牌。
當中vivo在一個月內推出兩款5G手機,成功打入高端線下市場,另外亦推450-550元的版本在線上銷售,相對之下華為及三星主要聚焦高端市場,而中興及中移動則主打600-650元的市場,另外小米(01810.HK)則成功佔據450-550元的市場。
IDC認為中國5G網絡建設受惠國家及政策支持,而營運商共建、共享網絡亦有幫助,但廣泛覆蓋仍需要一段時間,IDC估計出貨量將領先5G用戶,而幸運地由於其定價與4G比較仍是吸引,相信在明年將有助帶動行業增長勢頭。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.